Clinical Trial: An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Brief Summary: The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).

Detailed Summary:
Sponsor: XOMA (US) LLC

Current Primary Outcome: The proportion of subjects at Day 126 with complete closure of the PG target ulcer confirmed 2 weeks later (at Day 140) and without the need for rescue treatment [ Time Frame: Day 126 ]

Original Primary Outcome: Same as current

Current Secondary Outcome: The proportions of subjects at Day 126 with a reduction in the target ulcer area of ≥ 75% or ≥ 90% from baseline. [ Time Frame: Day 126 ]

Original Secondary Outcome:

Information By: XOMA (US) LLC

Dates:
Date Received: December 22, 2014
Date Started: December 2014
Date Completion:
Last Updated: April 25, 2016
Last Verified: April 2016